Share This Author
Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study
A simple six point score based on confusion, urea, respiratory rate, blood pressure, and age can be used to stratify patients with CAP into different management groups.
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
In patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.
Dexamethasone in Hospitalized Patients with Covid-19
- W. Lim
The members of the writing committee (Peter Horby, F.R.C.P., Jonathan R.P, Kathryn Rowan, Ph.D., Richard Haynes, D.M., and Martin J. Landray) assume responsibility for the overall content and integrity of this article.
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
A summary of the initial management of patients admitted to hospital with suspected community acquired pneumonia (CAP) is presented and the relevant microbiological investigations and empirical antibiotic choices recommended in patients with CAP are summarized.
Co-infections in people with COVID-19: a systematic review and meta-analysis
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
A prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19 found that low-dose dexamethasone reduced mortality in hospitalized patients with Cohen's disease who required respiratory support.
The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
- J. Mair-Jenkins, M. Saavedra-Campos, Yingjie Feng Jenkins
- MedicineThe Journal of infectious diseases
- 16 July 2014
Convalescent plasma may reduce mortality and appears safe, and should be studied within the context of a well-designed clinical trial or other formal evaluation, including for treatment of Middle East respiratory syndrome coronavirus CoV infection.
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines
S pneumoniae remains the most important pathogen to cover by initial antibiotic therapy in adults of all ages admitted to hospital with CAP and should also be covered in all patients with severe pneumonia and younger patients with non-severe infection.